Market capitalization | $53.55m |
Enterprise Value | $12.48m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 41.60 |
P/S ratio (TTM) P/S ratio | 178.50 |
P/B ratio (TTM) P/B ratio | 1.10 |
Revenue growth (TTM) Revenue growth | -70.65% |
Revenue (TTM) Revenue | $300.00k |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Talis Biomedical Corp:
1 Analyst has issued a forecast Talis Biomedical Corp:
Jun '24 |
+/-
%
|
||
Revenue | 0.30 0.30 |
71%
71%
|
|
Gross Profit | -0.94 -0.94 |
94%
94%
|
|
EBITDA | -48 -48 |
36%
36%
|
EBIT (Operating Income) EBIT | -49 -49 |
44%
44%
|
Net Profit | -51 -51 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Menlo Park, CA.
Head office | United States |
CEO | Robert Kelley |
Employees | 99 |
Founded | 2013 |
Website | talisbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.